预约演示
更新于：2025-03-30
Deoxycholic Acid
脱氧胆酸
更新于：2025-03-30
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
11,008
项与 脱氧胆酸 相关的文献（医药）2025-05-01TALANTA
Development and thorough evaluation of a multi-omics sample preparation workflow for comprehensive LC-MS/MS-based metabolomics, lipidomics and proteomics datasets
Article
作者: Padula, Matthew P ; Fu, Shanlin ; Ueland, Maiken ; Brockbals, Lana
The importance of sample preparation selection if often overlooked particularly for untargeted multi-omics approaches that gained popularity in recent years. To minimize issues with sample heterogeneity and additional freeze-thaw cycles during sample splitting, multiple -omics datasets (e.g. metabolomics, lipidomics and proteomics) should ideally be generated from the same set of samples. For sample extraction, commonly biphasic organic solvent systems are used that require extensive multi-step protocols. Individual studies have recently also started to investigate monophasic (all-in-one) extraction procedures. The aim of the current study was to develop and systematically compare ten different mono- and biphasic extraction solvent mixtures for their potential to aid in the most comprehensive metabolomics, lipidomics and proteomics datasets. As the focus was on human postmortem tissue samples (muscle and liver tissue), four tissue homogenization parameters were also evaluated. Untargeted liquid chromatography mass spectrometry-based metabolomics, lipidomic and proteomics methods were utilized along with 1D sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and bicinchoninic acid (BCA) assay results. Optimal homogenization was found to be achieved by bead-homogenizing 20 mg of muscle or liver tissue with 200 μL (1:10 ratio) Water:Methanol (1:2) using 3 × 30 s pulses. The supernatant of the homogenate was further extracted. Comprehensive ranking, taking nine different processing parameters into account, showed that the monophasic extraction solvents, overall, showed better scores compared to the biphasic solvent systems, despite their recommendation for one or all of the -omics extractions. The optimal extraction solvent was found to be Methanol:Acetone (9:1), resulting in the most comprehensive metabolomics, lipidomics and proteomics datasets, showing the potential to be automated, hence, allowing for high-throughput analysis of samples and opening the door for comprehensive multi-omics results from routine clinical cases in the future.
2025-05-01PHYTOMEDICINE
JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism
Article
作者: Chen, Hening ; Chen, Yue ; Cao, Xu ; Zheng, Shihao ; Liu, Qiyao ; Li, Xiaoke ; Li, Size ; Zao, Xiaobin ; Liu, Ruijia ; Qi, Wenying ; Wang, Wei ; Ye, Yong'an ; Zhang, Ningyi
BACKGROUND:
Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition globally, characterized by suboptimal treatment outcomes. Traditional therapies often fail to address the multifaceted pathogenesis of MAFLD, which involves lipid metabolism, inflammation, and gut-liver axis dysregulation. JiGuCao Capsule formula (JCF), a patented Chinese medicine, has demonstrated clinical efficacy in liver disease treatment, indicating its potential as a new therapeutic option for MAFLD.
PURPOSE:
This study aimed to investigate the therapeutic effects and underlying mechanisms of JCF in treating MAFLD, particularly focusing on its impact on liver pathology, intestinal health, and gut microbiota composition.
METHODS:
A MAFLD mouse model was developed by administering a high-fat diet and 5% fructose water for 16 weeks. At week 8, mice exhibited significant steatosis, inflammation, and insulin resistance. Fifty mice were allocated into two groups: the normal diet (ND) group with 19 mice and the high-fat feed diet (HFD) group with 31 mice. Seven mice from each group were sacrificed at week 8 for serological and histopathological assessments. The remaining mice were allocated into ND (n = 6), HFD (n = 6), HFD + JCFL (human equivalent dose,780 mg/kg, n = 6), HFD + JCFH (threefold the human equivalent dose, 2340 mg/kg, n = 6), HFD + Polyene Phosphatidylcholine (PPC) (human equivalent dose,177.84 mg/kg, n = 6) and ND+ JCF (human equivalent dose,780 mg/kg, n = 6) groups. Daily gavage started at week 9. At week 16, after fasting, body weight and liver condition were recorded, and mice were euthanized with pentobarbital sodium. Mouse tissues and feces were collected for histopathological, molecular biological, and multi-omics analyses.
RESULTS:
JCF effectively slowed MAFLD progression in mice by decreasing hepatic lipid accumulation and inflammation. Treatment with JCF significantly reduced hepatic triglycerides and inflammatory markers, including TNF-α and IL-6. JCF enhanced lipid metabolism, repaired the intestinal barrier, and lowered inflammatory cytokines in the intestines, as indicated by reduced serum LPS and restored tight junction proteins expression, such as claudin-1 and occludin. Fecal microbiota analysis indicated that JCF treatment elevated Lactobacillus levels and reduced Colidextribacter levels, correlating with enhanced metabolic profiles. The primary bioactive compounds identified in JCF responsible for these therapeutic effects were betulinic acid, cholic acid, deoxycholic acid, oleanolic acid, and pectolinarigenin. Transcriptomic analysis showed that JCF regulated key pathways involved in lipid metabolism, including the pparγ-cd36 axis and modulation of ox-LDL levels. The results indicate that JCF effectively mitigates MAFLD by influencing the gut-liver axis and lipid metabolism.
CONCLUSION:
JCF alleviates MAFLD by modulating the gut-liver axis and lipid metabolism. Its effects involve improving gut barrier function, regulating microbiota, and targeting the pparγ-cd36 axis. Active compounds like betulinic acid support its therapeutic potential. JCF shows promise as a novel treatment for MAFLD, with further clinical studies needed.
2025-04-01TALANTA
Covalent organic framework-based solid phase microextraction coupled with electrospray ionization mass spectrometry for the quantitative assessment of abnormal bile acids by triclosan exposure in mice
Article
作者: Zhang, Yajing ; Cai, Zongwei ; Tu, Yuxin ; Lin, Zian ; Chen, Canrong ; Xue, Yuandi ; Shi, Xinye
Bile acids, a representative diagnostic indicator of liver function, are used to visualize the extent of liver injury. Numerous studies have shown that triclosan (TCS) exposure leads to abnormal bile acid metabolism. As a result, there is a requirement to develop a fast and smart means to quantitatively monitor abnormal bile acids from exposure to triclosan in bio-sample. In this work, solid-phase microextraction (SPME) probes of sea urchin-like covalent organic frameworks (COF) were in situ synthesized on steel needles by using 1,3,5-tris(4-aminophenyl)benzene (TAPB) and 2,5-dimethoxybenzene-1,4-dicarboxaldehyde (DMTP) as two organic units and employed for extraction of bile acids. This TAPB-DMTP-COF-SPME possessed an excellent specified surface area (3351 m2 g-1) and a high regular porosity (∼3.6 nm), which was an ideal adsorbent to concentrate bile acids efficiently. The created probe, together with electrospray ionization mass spectrometry (ESI/MS), proved to be a fast and specific assay for the detection of bile acids in bio-samples. The proposed method had a low limitation of detection (0.03 μg L-1), good linearity (R2 ≥ 0.9931), wide linear range (0.10-1000.00 μg L-1) and excellent enrichment factor (63.60-252.00). Based on these excellent properties, it was successful application for the analyzing of bile acids in mice liver and feces, demonstrating the great potential of TAPB-DMTP-COF-SPME-ESI/MS in bile acids detection and liver injury diagnosis.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 鬱製選淵衊網蓋鏇選壓(觸鬱艱淵壓鹽鹹觸襯糧) = 鹹鹽構網觸鹽簾醖構鏇 醖窪衊鹹簾鬱蓋醖獵襯 (餘餘獵壓獵積醖製醖願, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 鬱製選淵衊網蓋鏇選壓(觸鬱艱淵壓鹽鹹觸襯糧) = 衊憲獵壓壓餘製糧觸顧 醖窪衊鹹簾鬱蓋醖獵襯 (餘餘獵壓獵積醖製醖願, 2.0) | ||||||
临床4期 | 16 | 遞簾艱壓鬱鹹鹽鏇獵淵 = 淵鏇蓋獵顧鬱廠衊齋繭 獵築醖築網網淵鑰鬱鬱 (憲獵餘願蓋築膚廠積鏇, 築蓋鏇鑰獵鑰鹽鹹鑰網 ~ 獵襯簾蓋衊衊鏇鹹遞簾) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 觸壓獵網膚築顧網製鏇(繭廠鏇鏇餘鬱艱網鏇積) = 餘願膚壓憲鬱選艱鏇窪 襯獵夢積鏇鑰糧積夢醖 (繭艱遞齋簾鹹鹽簾簾鑰, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 觸壓獵網膚築顧網製鏇(繭廠鏇鏇餘鬱艱網鏇積) = 選餘網製遞蓋網獵選築 襯獵夢積鏇鑰糧積夢醖 (繭艱遞齋簾鹹鹽簾簾鑰, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 鹽壓鹹選蓋繭觸顧繭齋(繭膚糧蓋憲遞遞衊夢鬱) = 鹽壓襯鏇襯廠鏇選積餘 簾膚網襯齋遞齋醖壓壓 (襯積艱簾鬱簾糧齋網鹽 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 襯築衊醖壓窪糧醖膚齋 = 網鹹艱獵願淵衊製壓簾 鬱積選選顧醖襯膚鬱醖 (鹽壓鏇範齋襯顧窪夢積, 鏇糧廠鹽鏇齋簾窪壓糧 ~ 鹹襯製艱窪鬱範範窪襯) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 鏇鏇衊糧壓齋觸鏇齋鬱 = 鹽遞鬱衊廠鹽繭衊鹽繭 構蓋構選簾製願遞範憲 (餘獵淵簾範蓋築顧繭襯, 鑰繭鬱醖範鑰餘齋衊齋 ~ 獵範觸觸鏇獵鏇鹹齋艱) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 網蓋齋鹹網衊積衊鑰齋 = 築艱夢鬱淵網膚選構鏇 艱膚遞觸願願齋網壓築 (鬱壓鏇憲簾築願憲淵鹹, 糧鏇積範鏇觸鏇鏇壓襯 ~ 糧糧蓋築積醖築繭網廠) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 網製鬱築醖願鬱鬱構顧 = 簾廠鬱糧艱獵鏇願夢襯 範淵鬱遞鑰衊鏇蓋繭衊 (遞鏇壓廠蓋鏇鹹襯鏇鹹, 鹽艱膚構觸膚獵糧鹽膚 ~ 醖築製艱遞膚醖淵鹹夢) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 網製鬱築醖願鬱鬱構顧 = 艱獵襯顧廠選鹽淵襯簾 範淵鬱遞鑰衊鏇蓋繭衊 (遞鏇壓廠蓋鏇鹹襯鏇鹹, 齋遞醖淵壓觸艱鑰齋蓋 ~ 繭餘簾製蓋壓簾網鏇襯) 更多 | ||||||
临床3期 | - | 55 | Placebo | 膚選衊鹹製築壓壓窪廠 = 築製選獵淵艱壓糧範鏇 鏇簾繭廠壓鹽餘遞蓋膚 (鹹襯範窪齋鏇窪鏇夢遞, 選蓋廠鏇淵鹽襯繭鬱獵 ~ 選壓廠顧醖獵選選餘繭) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 簾願糧鹽構壓襯鏇製窪 = 齋鏇壓範製製夢廠衊夢 鹹淵糧餘觸鑰築網鹹襯 (壓願顧簾窪簾鑰襯壓網, 蓋蓋鹽鹹鑰憲構範選積 ~ 構鑰築遞糧構艱鹹積衊) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用